SCHEMBL1875809

SCHEMBL1875809

CC(=O)Nc1ccc(NC2CCN(C(=O)OC(C)(C)C)CC2)cn1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.60
MAPT P10636 3/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
MAPK1 P28482 1/20 0.59
HTT P42858 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
PTPN2 P17706 1/20 0.51
PTPN1 P18031 1/20 0.51
PTPN6 P29350 1/20 0.51
GPR119 Q8TDV5 4/20 0.50
DDB1 Q16531 3/20 0.50
CRBN Q96SW2 3/20 0.50
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA9 Q16790 1/20 0.49
F13A1 P00488 1/20 0.48
TGM2 P21980 1/20 0.48
TGM1 P22735 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4243010 0.85 ALDH1A1 (0.73) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL16976307 0.84 ALDH1A1 (0.65) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL4240888 0.83 ALDH1A1 (0.64) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL25273779 0.82 ALDH1A1 (0.69) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL22324899 0.82 DDB1 (0.67) MAPTPTPN2PTPN1PTPN6GPR119
SCHEMBL2774486 0.82 ALDH1A1 (0.56) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL29716436 0.81 ALDH1A1 (0.61) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL31180977 0.81 ALDH1A1 (0.61) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL595609 0.81 ALDH1A1 (0.57) ALDH1A1MAPTNPC1RAB9AMAPK1
SCHEMBL2419028 0.81 ALDH1A1 (0.57) ALDH1A1MAPTNPC1RAB9AMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7939661-B2 Antidiabetic agents; somatostatin receptor subtype 5 modulators; noninsulin dependent diabetes mellitus; side effect reduction; synthesis HOFFMAN-LA ROCHE INC. (US) 2011-05-10 US disclosed
CN-101511817-A Pyridine-and quinoline-pyrimidine derivatives HOFFMANN LA ROCHE (CH) 2009-08-19 CN disclosed
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES HOFFMAN-LA ROCHE INC. 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064697-A1 PYRIDINE, QUINOLINE AND PYRIMIDINE DERIVATIVES SSTR5, SSTR3, NPY5R ALDH1A1 1558/4885MAPT 4308/4885NPC1 3153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.